CN120091831A - 用于治疗和/或预防肾囊性纤毛病的药物组合物 - Google Patents

用于治疗和/或预防肾囊性纤毛病的药物组合物 Download PDF

Info

Publication number
CN120091831A
CN120091831A CN202380074587.8A CN202380074587A CN120091831A CN 120091831 A CN120091831 A CN 120091831A CN 202380074587 A CN202380074587 A CN 202380074587A CN 120091831 A CN120091831 A CN 120091831A
Authority
CN
China
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
cyst
cells
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380074587.8A
Other languages
English (en)
Chinese (zh)
Inventor
长船健二
前伸一
西尾妙织
八反田文彦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hokkaido University NUC
Kyoto University NUC
Original Assignee
Hokkaido University NUC
Kyoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hokkaido University NUC, Kyoto University NUC filed Critical Hokkaido University NUC
Publication of CN120091831A publication Critical patent/CN120091831A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380074587.8A 2022-10-26 2023-10-26 用于治疗和/或预防肾囊性纤毛病的药物组合物 Pending CN120091831A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022-171387 2022-10-26
JP2022171387 2022-10-26
PCT/JP2023/038716 WO2024090521A1 (ja) 2022-10-26 2023-10-26 腎嚢胞性繊毛病の治療及び／又は予防のための医薬組成物

Publications (1)

Publication Number Publication Date
CN120091831A true CN120091831A (zh) 2025-06-03

Family

ID=90830957

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380074587.8A Pending CN120091831A (zh) 2022-10-26 2023-10-26 用于治疗和/或预防肾囊性纤毛病的药物组合物

Country Status (7)

Country Link
US (2) US12514834B2 (https=)
EP (1) EP4574171A4 (https=)
JP (1) JP7619587B2 (https=)
KR (1) KR20250089512A (https=)
CN (1) CN120091831A (https=)
AU (1) AU2023367530A1 (https=)
WO (1) WO2024090521A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7837529B1 (ja) * 2024-11-06 2026-03-31 国立大学法人京都大学 常染色体顕性（優性）多発性嚢胞腎治療用医薬組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3633026A4 (en) 2017-05-25 2021-03-10 Kyoto University METHOD FOR INDUCING THE DIFFERENTIATION OF A MESODERMAL INTERMEDIATE CELL TO A KIDNEY PRECURSOR CELL AND METHOD FOR INDUCING THE DIFFERENTIATION OF A PLURIPOTENT STEM CELL FROM A KIDNEY PRECURSOR CELL
JP2022180668A (ja) 2019-10-17 2022-12-07 学校法人杏林学園 腎機能障害の治療剤
US20240010989A1 (en) 2021-01-08 2024-01-11 Kyoto University Medium for culturing and expanding nephron progenitor cells, method for culturing and expanding nephron progenitor cells, and method for producing renal organoids
WO2022210968A1 (ja) 2021-03-31 2022-10-06 国立大学法人京都大学 嚢胞構造を有する人工集合管オルガノイド

Also Published As

Publication number Publication date
JPWO2024090521A1 (https=) 2024-05-02
EP4574171A4 (en) 2025-12-24
JP7619587B2 (ja) 2025-01-22
KR20250089512A (ko) 2025-06-18
US12514834B2 (en) 2026-01-06
US20260053763A1 (en) 2026-02-26
EP4574171A1 (en) 2025-06-25
WO2024090521A1 (ja) 2024-05-02
US20250170083A1 (en) 2025-05-29
AU2023367530A1 (en) 2025-03-27

Similar Documents

Publication Publication Date Title
US20240390427A1 (en) Methods and compositions relating to chondrisomes from cultured cells
Li et al. Human umbilical cord mesenchymal stem cell-derived exosomes improve ovarian function in natural aging by inhibiting apoptosis
CN112654366A (zh) 治疗或抑制亨廷顿病发作的方法
WO2022188788A1 (zh) 肝病调控制剂及其应用
US20240299391A1 (en) Compounds and methods for treatment of diamond blackfan anemia
AU2020203955B2 (en) Composition and method for inhibiting amyloid beta accumulation and/or aggregation
US20260053763A1 (en) Pharmaceutical composition for treating and/or preventing renal cystic ciliopathy
Liu et al. HIF-1 contributes to autophagy activation via BNIP3 to facilitate renal fibrosis in hypoxia in vitro and UUO in vivo
EP3691656A1 (en) Methods and compositions for treating urea cycle disorders, in particular otc deficiency
US12377092B2 (en) Polycomb inhibitors and uses thereof
Li et al. Apoptotic vesicles of mesenchymal stem cells promote M2 polarization and alleviate early-onset preeclampsia via miR-191-5p
WO2026082211A1 (zh) 修复卵巢功能的生物材料、制备方法及应用
Zhao et al. PD-L1 upregulation in activated fibroblasts promotes silica particle-induced pulmonary fibrosis
Liu et al. Vaping/e-cigarette-induced pulmonary extracellular vesicles contribute to exacerbated cardiomyocyte impairment through the translocation of ERK5
JP2014196268A (ja) フルベストラントを含む神経変性疾患の治療又は予防のための医薬組成物
CN113827622B (zh) 奇异变形杆菌外膜囊泡在制备预防或治疗骨溶解性疾病药物中的应用
US20250346864A1 (en) Modulation of satellite cell polarity and asymmetric cell division
JP2020515588A (ja) ミトコンドリア遺伝子疾患の処置方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination